Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven

Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right Read more about Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven[…]

Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business

Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong LPBN performance: 12.2%2 sales growth and 32.1% CORE EBITDA margin Production of the Read more about Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business[…]

NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms

. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets Read more about NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms[…]

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

Two new bioconjugation suites to provide high throughput conjugation for the commercialization  of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with a global biopharma company will generate around 200 new jobs in Visp (CH) biopark, with Read more about Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates[…]

Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data

. Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza:   “We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic.   “We are proud to support Moderna in the production of mRNA-1273. Our collaboration will allow for the manufacture Read more about Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data[…]

Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux

Pierre-Alain Ruffieux today commences his role as Chief Executive Officer, following his appointment in June 2020. Albert M. Baehny resumes his role as Chairman of the Board of Directors, after a year in the role of Chief Executive Officer ad interim. Quote from Albert Baehny, Chairman of the Board of Directors, Lonza: “I would like Read more about Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux[…]

Investor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance

Lonza provides the details of its new structural design, culture and external reporting 2023 Group guidance: double-digit sales growth, CORE EBITDA margin of around 33% – 35% and double-digit ROIC CAPEX in 2021 and 2022 is likely to remain at 2019 levels Biologics and Small Molecules are primary growth drivers, with contracted business up high Read more about Investor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance[…]

Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement

Strong operational performance maintained during COVID-19; sites remained open and protection of employees continues to be a top priority Landmark ten-year collaboration with Moderna on the mRNA1 platform. The current focus is to manufacture an mRNA-based vaccine (mRNA-1273) for the novel coronavirus Group sales growth of 7.7%2 and resilient CORE EBITDA margin of 29.1% Growth driven by Read more about Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement[…]

Sven Abend Leaves Lonza to Take CEO Position in Germany

•  Sven Abend has decided to resign from Lonza to take a CEO position in Germany. •  Recruitment plans are under way to appoint a permanent replacement. •  LSI is performing well and the segment carve-out process is nearing completion. Sven Abend has decided to resign from his position as a member of the Executive Read more about Sven Abend Leaves Lonza to Take CEO Position in Germany[…]

Lonza Appoints New Chief Executive Officer

The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020.   Pierre-Alain is currently Head of Global Pharma Technical Operations at Roche where he and his 12,000-strong team are responsible for all aspects of pharmaceutical commercial manufacturing and supply chain operations, technical, quality assurance and regulatory. Read more about Lonza Appoints New Chief Executive Officer[…]